PAO Group, Inc.

Recent News

  • PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook

    Sandusky, Ohio--(Newsfile Corp. - January 14, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today published a management outlook for 2021 on the company's strategy to develop and monetize the cannabis assets acquired last year. The strategic outlook is included in its entirety below:PAOG 2021 Cannabis Biopharmaceutical Strategic OutlookPAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications...

    2021-01-14 9:33 AM ET
  • PAOG Dividend Update Included In 2021 Cannabis Biopharmaceutical Strategic Update Tomorrow

    Sandusky, Ohio--(Newsfile Corp. - January 13, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced the upcoming update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook scheduled for tomorrow, Thursday Jan 14th, 2021, will include an update on the planned PAOG stock dividend to shareholders of Puration, Inc. (OTC Pink: PURA) in conjunction with PAOG's acquisition of hemp cultivation business from PURA.In 2020, PAOG acquired a hemp cultivation business from PURA and RespRx from Kali-Extracts, Inc. (OTC...

    2021-01-13 10:16 AM ET
  • PAOG Confirms Cannabis Biopharmaceutical Strategic Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

    Sandusky, Ohio--(Newsfile Corp. - January 12, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021.In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S. Patent...

    2021-01-12 11:51 AM ET
  • PAOG Cannabis Pharmaceutical and Nutraceutical 2021 Strategy Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

    Sandusky, Ohio--(Newsfile Corp. - January 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S....

    2021-01-11 11:31 AM ET
  • PAOG Confirms Q4 2020 Revenue from Cannabis Asset Acquisition

    Sandusky, Ohio--(Newsfile Corp. - January 8, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed that the Company expects to realize and report in Q4 2020 the first revenue from assets acquired in the course of 2020.In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No....

    2021-01-08 11:44 AM ET
  • PAOG Takes Major CBD Pharmaceutical Development Step Forward

    Sandusky, Ohio--(Newsfile Corp. - January 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product.PAOG today announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough, Massachusetts. PAOG has engaged Veristat to assist in advancing PAOG with its proprietary Cannabidiol (CBD) extract for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward initiating an Investigational New Drug application (IND) with the Food and...

    2021-01-05 11:18 AM ET
  • PAOG Expects to Report First Post Acquisition Revenue in Q4 2020

    Sandusky, Ohio--(Newsfile Corp. - December 22, 2020) -  PAO Group, Inc. (OTC Pink: PAOG) today announced that the company expects to realize and report in Q3 2020 the first revenue from assets acquired in the course of 2020.In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960...

    2020-12-22 12:16 PM ET
  • PAOG Develops CBD Nutraceutical for $12.7 Billion from Patented Extract Process

    Sandusky, Ohio--(Newsfile Corp. - December 18, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced the company expects to generate its first revenue next year in 2021 from its Cannabidiol (CBD) extraction technology, RespRx, acquired in July of this year, 2020.Yesterday, PAOG announced an engagement with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary CBD extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive...

    2020-12-18 3:09 PM ET